Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 91 entries
View as:

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06042894 Org: User:
Start: 12/12/23 End: 12/31/25 Due: 12/31/26

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05470348 Org: User:
Start: 08/11/22 End: 12/31/25 Due: 12/31/26

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06498986 Org: User:
Start: 07/31/24 End: 08/31/26 Due: 08/31/27

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05393427 Org: User:
Start: 02/15/22 End: 06/30/25 Due: 06/30/26

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05956587 Org: User:
Start: 01/29/24 End: 11/30/25 Due: 11/30/26

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma

Phase: N/A Priority: Normal
NCT ID: NCT06787664 Org: User:
Start: 01/16/25 End: 12/31/27 Due: 12/31/28

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05880706 Org: User:
Start: 07/19/23 End: 07/31/25 Due: 07/31/26

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05990803 Org: User:
Start: 11/06/23 End: 11/30/25 Due: 11/30/26

A Study of SI-F019 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04851444 Org: User:
Start: 03/30/21 End: 09/20/21 Due: 09/20/22

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06437522 Org: User:
Start: 06/07/24 End: 06/30/26 Due: 06/30/27

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05785039 Org: User:
Start: 04/20/23 End: 12/31/25 Due: 12/31/26

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06405425 Org: User:
Start: 05/29/24 End: 05/31/26 Due: 05/31/27

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06475300 Org: User:
Start: 06/25/24 End: 07/31/26 Due: 07/31/27

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05965856 Org: User:
Start: 12/11/23 End: 12/31/25 Due: 12/31/26

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06008054 Org: User:
Start: 11/16/23 End: 12/31/25 Due: 12/31/26

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05194982 Org: User:
Start: 11/29/21 End: 12/31/25 Due: 12/31/26

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06598787 Org: User:
Start: 10/17/24 End: 10/31/26 Due: 10/31/27

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05803018 Org: User:
Start: 06/25/23 End: 06/30/25 Due: 06/30/26

A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06469008 Org: User:
Start: 06/27/24 End: 07/31/26 Due: 07/31/27

A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06475131 Org: User:
Start: 07/18/24 End: 07/31/26 Due: 07/31/27

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06471205 Org: User:
Start: 08/02/24 End: 07/31/26 Due: 07/31/27

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06445400 Org: User:
Start: 06/19/24 End: 06/30/26 Due: 06/30/27

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06382142 Org: User:
Start: 06/21/24 End: 06/30/26 Due: 06/30/27

Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection

Phase: N/A Priority: Normal
NCT ID: NCT03853369 Org: User:
Start: 02/18/19 End: 12/30/19 Due: 12/30/20

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Phase: N/A Priority: Normal
NCT ID: NCT05485753 Org: User:
Start: 02/10/23 End: 12/31/25 Due: 12/31/26